Dec 16 (Reuters) - Pfizer (PFE.N) on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.
The drugmaker expects adjusted profit of between $2.80 and $3 per share for the coming year, below analysts’ average estimate of $3.05 per share, according to data compiled by LSEG.
It expects revenue for the year in the range of $59.5 billion to $62.5 billion, compared with estimates of $61.59 billion.
That includes the expectation of revenue from COVID-19 products being about $1.5 billion lower than what was expected in 2025.

Pfizer forecasts 2026 profit below Wall Street estimates due to lower COVID product sales. The company expects adjusted profit between $2.80 and $3 per share, below the $3.05 per share average estimate. Revenue is expected to be between $59.5 billion and $62.5 billion, with COVID-19 product revenue about $1.5 billion lower than expected in 2025.

- Pfizer forecasts 2026 profit below Wall Street estimates due to expected lower sales of COVID-19 products, resulting in a 1.6% drop in its shares.  
- The company anticipates an adjusted profit of $2.80 to $3 per share, under the average analyst estimate of $3.05 per share.  
- Revenue projections range from $59.5 billion to $62.5 billion, reflecting a $1.5 billion decrease in expected revenue from COVID-19 products compared to 2025.

Pfizer forecasts 2026 profit below expectations on lower COVID product sales